Press Resease

Calcium Channel Blocker Market - Global Industry Analysis

Calcium Channel Blocker Market By Drug Class (Dihydropyridine And Non-Dihydropyridine) For Hypertension, Angina Pectoris, Pregnancy, Obesity And Other - Global Industry Perspective, Comprehensive Analysis And Forecast, 2020 – 2028

Published Date: 03-Jun-2021 Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-717 Status : Published

The Global Calcium Channel Blocker market accounted for USD 12.94 Billion in 2020 and is expected to reach USD 20.05 Billion by 2028, growing at a CAGR of around 5.6% between 2021 and 2028.

Description

Market Overview    

The Global Calcium Channel Blocker market accounted for USD 12.94 Billion in 2020 and is expected to reach USD 20.05 Billion by 2028, growing at a CAGR of around 5.6% between 2021 and 2028.   

Calcium channel blockers are a type of medications that lower the blood pressure by preventing calcium from entering the cells of your heart and arteries. Calcium causes the heart and arteries to contract more strongly. By blocking Calcium, calcium channel blockers allow blood vessels to relax and open thereby increase the supply of blood and oxygen to the heart. Doctor generally prescribe a calcium channel blocker to treat high blood pressure. These drugs are also used to cure chest pain, coronary heart disease, an irregular heartbeat. These drugs also prevent migraine headaches. Scientists are currently exploring other potential uses for calcium channel blockers. For example, by reducing high blood pressure, calcium channel breakers may be able to lower the risk of Alzheimer’s disease.

Changing lifestyle of people across all regions is leading to an increase in the number of stress related diseases or cardiovascular diseases, which is a major factor, which in turn is anticipated to boost the calcium channel blocker market growth. 

COVID-19 Impact Analysis

The global Calcium Channel Blocker market has witnessed a very slight decline due to the lockdown enforcement placed by governments in order to contain COVID spreading. The restrictions imposed by various nations to contain COVID had stopped the production resulting in a disruption across the whole supply chain. However, the global markets are slowly opening to their full potential and theirs a surge in demand of calcium channel blocker. The market would remain bullish in upcoming year.

The significant decrease in the global Calcium Channel Blocker market size in 2020 is estimated on the basis of the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.

Growth Factors

Change in the lifestyle of people across the world likely to augment the hypertension and stress related diseases which in turn anticipated to drive the growth of the Calcium Channel Blocker market. Calcium Channel Blocker are the drugs that are used against hypertension and chest pain. It slows the calcium movement that helps to widen the blood vessels thereby reducing blood pressure and makes it easier for heart to pump the blood. According to World Health Organization, approximately 1.13 billion of people globally have hypertension. Also, Cardiovascular diseases are one of the leading causes of the death. Calcium Channel Blocker are effective against this indications. This increased in demand is likely to spur the growth of Calcium Channel Blocker market. However, the side effects headache, rapid heart rate, and constipation are likely to hamper the overall demand for calcium channel blocker market.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Drug Class Segment Analysis Preview 

Calcium channel blocker market is segmented into two types: Dihydropyridine and Non-Dihydropyridine. Dihydropyridine is one of the important groups of calcium channel blocker which held approximately 63.2% of the overall market in 2020. Dihydropyridine class is expected to be the largest segment in the market due to growing demand from pharmaceutical industry. Lower cost and easy availability of the products is expected to propel the growth of Dihydropyridine segment. Dihydropyridine class of CCB market is further sub-segmented into Amlodipine, Cilnidipine, Felodipine, Verapamil, Diltiazem, Isradipine, Nicardipine, Nisoldipine, Nifedipine, and others.Whereas, the Non-Dihydropyridine market is sub-segmented into Diltiazem and Verapamil.

Application Segment Analysis Preview

The market is segmented into five types: the calcium hypertension, angina pectoris, pregnancy, anti-obesity and other. Hypertension segment hold the major share in the calcium channel blocker market in 2020. For instance, in hypertension, Verapamil and Amlodipine are increasingly used in the pharmaceutical industry.  Amlopdipine is a first line therapy for the treatment obesity, angina pectoris and others.

Key Market Players & Competitive Landscape

Major market players of Calcium Channel Blocker market comprise Pfizer Inc., AstraZeneca Plc., Bayer Healthcare LLC., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson, Abcam, AbMole Bioscience, and Clearsynth among others play an important role.

The global Calcium Channel Blocker Market is segmented as follows:

By Drugs Class

  • Dihydropyridine
  • Non-Dihydropyridine

By Application

  • Angina Pectoris
  • Hypertension
  • Pregnancy
  • Obesity
  • Other
  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

By Region

Table Of Content

  • Chapter No. 1: Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2: Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Drugs Class
        • 2.1.1.2. Market Attractiveness Analysis, By Application
      • 2.1.1.3 Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Calcium Channel Blocker Market, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3: COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4: Calcium Channel Blocker Market – Application Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Drugs Class, 2020 & 2028
    • 4.2. Dihydropyridine
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.2.4 Amuldipine
      • 4.2.4.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.2.5 Cilnidipine
      • 4.2.5.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.2.6 Felodipine
      • 4.2.6.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.2.7 Isradipine
      • 4.2.7.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.2.8 Nicardipine
      • 4.2.8.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.2.9 Nisuldipine
      • 4.2.9.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.2.10 Nifedipine
      • 4.2.10.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.2.11 Others
      • 4.2.11.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Non-Dihydropyridine
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3.4 Diltiazem
      • 4.3.4.1 Key Market Trends, Growth Factors, & Opportunities
    • 4.3.5 Verapamil
      • 4.3.5.1 Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Calcium Channel Blocker Market – Application Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Application, 2020 & 2028
    • 5.2. Angina Pectoris
      • 5.2.1. Market Size and Forecast, By Region (USD Billion)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Hypertension
      • 5.3.1. Market Size and Forecast, By Region (USD Billion)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.4. Pregnancy
      • 5.4.1. Market Size and Forecast, By Region (USD Billion)
      • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.5. Obesity
      • 5.4.1. Market Size and Forecast, By Region (USD Billion)
      • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.6. Others
      • 5.4.1. Market Size and Forecast, By Region (USD Billion)
      • 5.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.4.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Calcium Channel Blocker Market – Regional Analysis
    • 6.1. Overview
      • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 6.2. North America
      • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.2.2. North America Market Revenue, By Drug Class, 2016 – 2028
      • 6.2.3. North America Market Revenue, By Application, 2016 – 2028
      • 6.2.5. U.S.
        • 6.2.5.1. U.S. Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.5.2. U.S. Market Revenue, By Application, 2016 – 2028
      • 6.2.6. Canada
        • 6.2.6.1. Canada Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.6.2. Canada Market Revenue, By Application, 2016 – 2028
      • 6.2.7. Mexico
        • 6.2.7.1. Mexico Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.7.2. Mexico Market Revenue, By Application, 2016 – 2028
    • 6.3. Europe
      • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.3.2. Europe Market Revenue, By Drug Class, 2016 – 2028
      • 6.3.3. Europe Market Revenue, By Application, 2016 – 2028
      • 6.3.5. Germany
        • 6.3.5.1. Germany Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.5.2. Germany Market Revenue, By Application, 2016 – 2028
      • 6.3.6. France
        • 6.3.6.1. France Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.6.2. France Market Revenue, By Application, 2016 – 2028
      • 6.3.7. U.K.
        • 6.3.7.1. U.K. Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.7.2. U.K. Market Revenue, By Application, 2016 – 2028
      • 6.3.8. Italy
        • 6.3.8.1. Italy Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.8.2. Italy Market Revenue, By Application, 2016 – 2028
      • 6.3.9. Spain
        • 6.3.9.1. Spain Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.9.2. Spain Market Revenue, By Application, 2016 – 2028
      • 6.3.10. Rest of Europe
        • 6.3.10.1. Rest of Europe Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.10.2. Rest of Europe Market Revenue, By Application, 2016 – 2028
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.4.2. Asia Pacific Market Revenue, By Drug Class, 2016 – 2028
      • 6.4.3. Asia Pacific Market Revenue, By Application, 2016 – 2028
      • 6.4.5. China
        • 6.4.5.1. China Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.5.2. China Market Revenue, By Application, 2016 – 2028
      • 6.4.6. Japan
        • 6.4.6.1. Japan Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.6.2. Japan Market Revenue, By Application, 2016 – 2028
      • 6.4.7. India
        • 6.4.7.1. India Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.7.2. India Market Revenue, By Application, 2016 – 2028
      • 6.4.8. South Korea
        • 6.4.8.1. South Korea Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.8.2. South Korea Market Revenue, By Application, 2016 – 2028
      • 6.4.9. South-East Asia
        • 6.4.9.1. South-East Asia Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.9.2. South-East Asia Market Revenue, By Application, 2016 – 2028
      • 6.4.10. Rest of Asia Pacific
        • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.10.2. Rest of Asia Pacific Market Revenue, By Application, 2016 – 2028
    • 6.5. Latin America
      • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.5.2. Latin America Market Revenue, By Drug Class, 2016 – 2028
      • 6.5.3. Latin America Market Revenue, By Application, 2016 – 2028
      • 6.5.5. Brazil
        • 6.5.5.1. Brazil Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.5.2. Brazil Market Revenue, By Application, 2016 – 2028
      • 6.5.6. Argentina
        • 6.5.6.1. Argentina Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.6.2. Argentina Market Revenue, By Application, 2016 – 2028
      • 6.5.7. Rest of Latin America
        • 6.5.7.1. Rest of Latin America Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.7.2. Rest of Latin America Market Revenue, By Application, 2016 – 2028
    • 6.6. The Middle-East and Africa
      • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.6.2. The Middle-East and Africa Market Revenue, By Drug Class, 2016 – 2028
      • 6.6.3. The Middle-East and Africa Market Revenue, By Application, 2016 – 2028
      • 6.6.5. GCC Countries
        • 6.6.5.1. GCC Countries Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.5.2. GCC Countries Market Revenue, By Application, 2016 – 2028
      • 6.6.6. South Africa
        • 6.6.6.1. South Africa Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.6.2. South Africa Market Revenue, By Application, 2016 – 2028
      • 6.6.7. Rest of Middle-East Africa
        • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.7.2. Rest of Middle-East Africa Market Revenue, By Application, 2016 – 2028
  • Chapter No. 7: Calcium Channel Blocker Market – Industry Analysis
    • 7.1. Introduction
    • 7.2. Market Drivers
      • 7.2.1. Driving Factor 1 Analysis
      • 7.2.2. Driving Factor 2 Analysis
    • 7.3. Market Restraints
      • 7.3.1. Restraining Factor Analysis
    • 7.4. Market Opportunities
      • 7.4.1. Market Opportunity Analysis
    • 7.5. Porter’s Five Forces Analysis
    • 7.6. PEST Analysis
    • 7.7. Regulatory Landscape
    • 7.8. Technology Landscape
    • 7.9. Regional Market Trends
      • 7.9.1. North America
      • 7.9.2. Europe
      • 7.9.3. Asia Pacific
      • 7.9.4. Latin America
      • 7.9.5. The Middle-East and Africa
    • 7.10. Pricing Analysis
    • 7.11. Value Chain Analysis
    • 7.12. Downstream Buyers
    • 7.13. Distributors/Traders List
  • Chapter No. 8: Competitive Landscape
    • 8.1. Company Market Share Analysis – 2020
      • 8.1.1. Global Calcium Channel Blocker Market: Company Market Share, 2020
      • 8.1.2. Global Calcium Channel Blocker Market, Company Market Revenue, 2017 – 2020 (USD Billion)
      • 8.1.3. Global Calcium Channel Blocker Market, Company Y-o-Y Growth, 2017 – 2020(%)
      • 8.1.4. Global Calcium Channel Blocker Market: Radar Determinant Chart, 2020
    • 8.2. Strategic Developments
      • 8.2.1. Acquisitions & Mergers
      • 8.2.2. New Product Launch
      • 8.2.3. Regional Expansion
    • 8.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 9: Company Profiles
    • 9.1. Pfizer Inc
      • 9.1.1. Company Overview
      • 9.1.2. Key Executives
      • 9.1.3. Product Portfolio
      • 9.1.4. Financial Overview
      • 9.1.5. Operating Business Segments
      • 9.1.6. Business Performance
      • 9.1.7. Recent Developments
    • 9.2. Astazenca Plc
    • 9.3. Bayer Healthcare LLC.
    • 9.4. GlaxoSmithKline plc
    • 9.5. Johnson & Johnoson
    • 9.6. Abcam
    • 9.7. AbMule Bioscience
    • 9.8. Clearsynth
    • 9.9. Sanofi S. A.
  • Chapter No. 10: Marketing Strategy Analysis
    • 10.1. Marketing Channel
    • 10.2. Direct Marketing
    • 10.3. Indirect Marketing
    • 10.4. Marketing Channel Development Trends
    • 10.5. Economic/Pulitical Environmental Change
  • Chapter No. 11: Research Methodology
    • 11.1. Research Methodology
    • 11.2. Phase I - Secondary Research
    • 11.3. Phase II - Data Modeling
      • 11.3.1. Company Share Analysis Model
      • 11.3.2. Revenue Based Modeling
    • 11.4. Phase III - Primary Research
    • 11.5. Research Limitations
      • 11.5.1. Assumptions

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Drug Class
FIG NO. 2. Market Attractiveness Analysis, By Application
FIG NO. 3. Market Attractiveness Analysis, By Region
FIG NO. 4. Global Calcium Channel Blocker Market Revenue, 2016 – 2028 (USD Billion)
FIG NO. 5 Impact of COVID-19 Pandemic in North America Countries
FIG NO. 6. Market Revenue Share, By Drug Class, 2020 & 2028
FIG NO. 7. Global Calcium Channel Blocker Market for Dihydropyridine, Revenue (USD Billion) 2016 – 2028
FIG NO. 8. Comparative Revenue Analysis of Calcium Channel Blocker Market for Dihydropyridine, By Country, 2020 & 2028
FIG NO. 9. Global Calcium Channel Blocker Market for Non-Dihydropyridine, Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of Calcium Channel Blocker Market for Non-Dihydropyridine, By Country, 2020 & 2028
FIG NO. 11. Market Revenue Share, By Application, 2020 & 2028
FIG NO. 12. Global Calcium Channel Blocker Market for Hypertension, Revenue (USD Billion) 2016 – 2028
FIG NO. 13. Comparative Revenue Analysis of Calcium Channel Blocker Market for Hypertension, By Country, 2020 & 2028
FIG NO. 14. Global Calcium Channel Blocker Market for Angina pectoris, Revenue (USD Billion) 2016 – 2028
FIG NO. 15. Comparative Revenue Analysis of Calcium Channel Blocker Market for Angina pectoris, By Country, 2020 & 2028
FIG NO. 16. Global Calcium Channel Blocker Market for Pregnancy, Revenue (USD Billion) 2016 – 2028
FIG NO. 17. Comparative Revenue Analysis of Calcium Channel Blocker Market for Pregnancy, By Country, 2020 & 2028
FIG NO. 18. Global Calcium Channel Blocker Market for Obesity, Revenue (USD Billion) 2016 – 2028
FIG NO. 19. Comparative Revenue Analysis of Calcium Channel Blocker Market for Obesity, By Country, 2020 & 2028
FIG NO. 20. Global Calcium Channel Blocker Market for Others, Revenue (USD Billion) 2016 – 2028
FIG NO. 21. Comparative Revenue Analysis of Calcium Channel Blocker Market for Others, By Country, 2020 & 2028
FIG NO. 22. Global Calcium Channel Blocker Market Revenue Share, By Region, 2020 & 2028
FIG NO. 23. North America Calcium Channel Blocker Market Revenue, 2016 - 2028 (USD Billion)
FIG NO. 24. Porter’s Five Forces Analysis for Global Calcium Channel Blocker Market
FIG NO. 25. PEST Analysis for Global Calcium Channel Blocker Market
FIG NO. 26. Pricing Analysis for Global Calcium Channel Blocker Market
FIG NO. 27. Value Chain Analysis for Global Calcium Channel Blocker Market
FIG NO. 28. Company Share Analysis, 2019
FIG NO. 29. Radar Determinant Chart, 2019
FIG NO. 30. Company Strategic Developments – Heat Map Analysis
FIG NO. 31. Pfizer Inc Business Segment Revenue Share, 2020 (%)
FIG NO. 32. Pfizer Inc Geographical Segment Revenue Share, 2020 (%)
FIG NO. 33. Market Channels
FIG NO. 34. Marketing Channel Development Trend
FIG NO. 35. Growth in World Gross Product, 2008-2018
FIG NO. 36. Research Methodology – Detailed View
FIG NO. 37. Research Methodology
 


List of Tables 

TABLE NO. 1. Global Calcium Channel Blocker Market: Snapshot
TABLE NO. 2. Quarterly Calcium Channel Blocker Market Revenue by Region, 2020
TABLE NO. 3 Quarterly Calcium Channel Blocker Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
TABLE NO. 6. Global Calcium Channel Blocker Market for Dihydropyridine, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global Calcium Channel Blocker Market for Non-Dihydropyridine, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 8. Global Calcium Channel Blocker Market for Hypertension, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 9. Global Calcium Channel Blocker Market for Angina pectoris, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 10. Global Calcium Channel Blocker Market for Pregnancy, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 11. Global Calcium Channel Blocker Market for Obesity, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 12. Global Calcium Channel Blocker Market for Others, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 13. Global Calcium Channel Blocker Market Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 14. North America Calcium Channel Blocker Market Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 15. North America Calcium Channel Blocker Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 16. North America Calcium Channel Blocker Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 17. U.S. Calcium Channel Blocker Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 18. U.S. Calcium Channel Blocker Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 19. Canada Calcium Channel Blocker Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 20. Canada Calcium Channel Blocker Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 21. Mexico Calcium Channel Blocker Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 22. Mexico Calcium Channel Blocker Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 23. Drivers for the Calcium Channel Blocker Market: Impact Analysis
TABLE NO.24. Restraints for the Calcium Channel Blocker Market: Impact Analysis
TABLE NO. 25. Major Buyers of Calcium Channel Blocker
TABLE NO. 26. Distributors/Traders List of Calcium Channel Blocker  
TABLE NO. 27. Global Calcium Channel Blocker Market, Company Market Revenue, 2016 – 2019 (USD Billion)
TABLE NO. 28. Global Calcium Channel Blocker Market, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Calcium Channel Blocker market. Zion Research has collected and analyzed key data belong to the global Calcium Channel Blocker market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Calcium Channel Blocker across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Calcium Channel Blocker industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Calcium Channel Blocker market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Calcium channel blockers (CCBs) or calcium antagonists are among the most widely used drugs in cardiovascular medicine. CCBs promote vasodilator activity and thus act by reducing calcium influx into vascular smooth muscle cells by interfering with voltage-operated calcium channels in the cell membrane. This activity of calcium channel blockers helps for treating Hypertension and various other cardiovascular diseases.

The market of global calcium channel blocker has been accelerated by rising prevalence of hypertension across the globe. Moreover, calcium channel blockers are an essential class of cardiovascular drug prescribed by a physician for the treatment of hypertension which helps in propelling the growth of calcium channel blocker market. Furthermore, its wide application in pharmaceutical industry is expected to fuel the growth of global calcium channel blocker market. As well, the rising percentage of the obese population is also considered as a major driving factor for the growth of CCB market.  However, availability of alternatives and certain side effect of CCB can restrict the growth of calcium channel blocker market. Nonetheless, ongoing research and development and combination therapy will serve as major opportunities for upcoming growth of calcium channel blocker market.

Calcium Channel Blocker Market

Based on product, calcium channel blocker market segmented into two types: Dihydropyridine and Non-Dihydropyridine. Dihydropyridine market is further sub-segmented into Amlodipine, Cilnidipine, Felodipine, Verapamil, Diltiazem, Isradipine, Nicardipine, Nisoldipine, Nifedipine and others. In 2016, amlodipine held the largest market share in terms of total revenue generation in the Dihydropyridine market.  This growth is attributed due to the most preference by the physician or consultant towards amlodipine over the other drugs.

Based on application, calcium channel blocker market segmented into five types: hypertension, angina pectoris, pregnancy, anti-obesity and other. Hypertension dominated the calcium channel blockers market in 2016. This segment accounted for the largest market share in term of revenue generation in 2016. The growth of hypertension market is attributed due to large hypertension patient population than any other illness which can be treated by CCB.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global calcium channel blocker include Pfizer Inc., AstraZeneca plc., bayer healthcare llc., GlaxoSmithKline plc., Sanofi S.A., Johnson & Johnson, Abcam, AbMole Bioscience, and Clearsynth.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The global Calcium Channel Blocker Market was valued at USD 12.94 billion in 2020.

The global Calcium Channel Blocker Market is expected to reach USD 20.05 billion by 2028, growing at a CAGR of 5.6% between 2021 to 2028.

Some of the key factors driving the global Calcium Channel Blocker Market growth are, Change in the lifestyle of people across the world likely to augment the hypertension and stress related diseases.

North America accounted for the largest share in the market in terms of consumption. Rising percentage of obese and hypertension patient population in Asia Pacific is expected to prompt the growth of calcium channel blocker market within the forecast period.

Some of the major companies operating in Calcium Channel Blocker Market are Pfizer Inc., AstraZeneca Plc., Bayer Healthcare LLC., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson, Abcam, AbMole Bioscience, and Clearsynth among others play an important role.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed